Literature DB >> 30439454

Neuropeptide receptors as potential pharmacological targets for obesity.

Beatriz T Meneguetti1, Marlon H Cardoso2, Camila F A Ribeiro1, Mário R Felício3, Ingrid B Pinto1, Nuno C Santos3, Cristiano M E Carvalho1, Octávio L Franco4.   

Abstract

Obesity is a chronic multifactorial disease, characterized by an excessive accumulation of adipose tissue. It is usually the result of excessive food intake and/or low energy expenditure. Obesity can be triggered by lifestyle, nutritional, genetic, environmental, hormonal and psychological factors. Several strategies are used to treat obesity, including dietary reeducation, with balanced food intake, increased physical exercise, in order to promote energy expenditure and to overcome the insufficiency in weight reduction by other strategies, and administration of drugs. However, these medications are associated to undesirable side effects, resulting in a high withdrawal rate. Several studies have been focused on the development of compounds that act in the hypothalamic region where the center of the regulation of hunger and satiety is located. Some of them target the activity of endogenous peptides, such as ghrelin pancreatic polypeptide, peptide YY and neuropeptide Y, as well as their receptors. This review addresses the importance of understanding the neuropeptide/peptide hormones and their receptors for the development of novel anti-obesity compounds that may aid in weight reduction as a promising alternative for the treatment of obesity.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Food intake; GPCRs; Hypothalamus; Neuropeptides; Obesity; Peptide hormones

Mesh:

Substances:

Year:  2018        PMID: 30439454     DOI: 10.1016/j.pharmthera.2018.11.002

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  3 in total

Review 1.  Satiety Associated with Calorie Restriction and Time-Restricted Feeding: Peripheral Hormones.

Authors:  Debra K M Tacad; Ashley P Tovar; Christine E Richardson; William F Horn; Giri P Krishnan; Nancy L Keim; Sridevi Krishnan
Journal:  Adv Nutr       Date:  2022-06-01       Impact factor: 11.567

Review 2.  Neuropeptide signalling systems - An underexplored target for venom drug discovery.

Authors:  Helen C Mendel; Quentin Kaas; Markus Muttenthaler
Journal:  Biochem Pharmacol       Date:  2020-06-30       Impact factor: 5.858

3.  Spexin as an indicator of beneficial effects of exercise in human obesity and diabetes.

Authors:  Abdelkrim Khadir; Sina Kavalakatt; Dhanya Madhu; Sriraman Devarajan; Jehad Abubaker; Fahd Al-Mulla; Ali Tiss
Journal:  Sci Rep       Date:  2020-06-30       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.